Eli Lilly acquires Kelonia Therapeutics for $7bn Lilly will gain access to Kelonia's experimental cancer therapy for multiple myeloma that reprogrammes patients' immune cells in the body.

Is Eli Lilly hedging its bets outside of the obesity market?

The company plans to buy Kelonia Therapeutics for up to $7bn, gaining access to an experimental multiple myeloma therapy that reprogrammes patients’ immune cells inside the body.

Learn more: www.emjreviews.com/emj-gold/new...

Calling all those in cancer care.

In this new column, Dr Henar Hevia, J&J Innovative Medicine, explores how real-world evidence and better decision-making can improve outcomes, personalise treatment and close the gap between innovation and care.

Read now: hubs.la/Q04cv8dL0

More from #WIREDHealth:

Kathleen Fisher, CEO, ARIA, shared a story about failure.

A synthetic blood programme didn’t work as intended. But the same technology showed potential elsewhere. It eventually led to Moderna’s mRNA platform.

Sign up for more: www.emjreviews.com/mailing-list/

The team are at #WIREDHealth to capture the key insights for pharma.

Top moment so far: Lord Vallance calls on UK funds to invest in life sciences, noting only Canadian funds, and pensioners, are currently reaping the rewards.

Sign up for full round up: www.emjreviews.com/mailing-list/

Amazon launches AI platform for faster drug discovery Amazon Web Services has launched a new AI platform to help drug developers identify and test potential drug candidates more efficiently.

Amazon Web Services has launched a new artificial intelligence platform for drug discovery, which, crucially, researchers can use without writing code for the first time.

Early adopters include @mskcancercenter.bsky.social.

Learn more: www.emjreviews.com/emj-gold/new...

#AIinHealthcare

Novo partners with OpenAI to boost drug development Discover more about the new partnership between Danish drugmaker Novo Nordisk and tech giant OpenAI.

Update: Novo Nordisk join forces with with OpenAI.

“This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare," said President and CEO Mike Doustdar.

Read more: www.emjreviews.com/emj-gold/new...

Is CMS reshaping cannabinoid access policy through the back door?

A new federal pilot allows Medicare organisations to discuss and furnish hemp-derived CBD products - without FDA approval and without going through standard regulatory process.

🔗: hubs.la/Q04bp4X70

Novo Nordisk has launched a 7.2 mg semaglutide injection in the US, nearly three times the previous highest available dose.

Learn more: www.emjreviews.com/emj-gold/new...

Cardiovascular disease costs the world $680bn a year. A new OHE report suggests up to $480bn of that could be avoided.

The key? Early detection and management of moderately elevated LDL-C at scale.

Read more: www.emjreviews.com/emj-gold/new...

World Health Day: VML's top 10 healthcare trends Healthcare is moving into a new phase in which trust, not just treatment, will shape success, according to a new VML Health report.

Great science means nothing if patients can't trust, understand or use it.

VML Health's Health Futures 2026 report warns that rising misinformation is eroding patient confidence faster than innovation can rebuild it.

Read more: www.emjreviews.com/emj-gold/new...

#WorldHealthDay

Lilly’s weight loss pill wins FDA approval Eli Lilly won FDA approval on 1 April 2026 for a once-daily oral GLP-1, orforglipron. Read more about the drug and its rollout.

Big news in obesity care: Eli Lilly’s once-daily oral GLP-1, orforglipron, has received FDA approval.

In clinical trials, patients achieved ~12% weight loss at the highest dose, alongside improvements in key cardiovascular risk factors.

Read more: www.emjreviews.com/emj-gold/new...

Month in pharma news, explained – March 2026 In this monthly news roundup, we take a look back at top moments from the pharmaceutical industry. It’s time to reflect on March 2026.

Month in pharma: March 2026, explained 👇

From Takeda's restructure to fuel its late-stage pipeline, to space-based drug manufacturing gaining traction in the UK, March showed the industry is never a boring place to be.

Discover the full round up: www.emjreviews.com/emj-gold/new...

Promotion of biologics under fire from FDA For pharma marketers, the recent FDA letters to four biologics companies signal a continued rise in enforcement activity from the agency.

Is FDA scrutiny of biologics marketing increasing?

The CBER has ended a period of relative dormancy with a rare quartet of untitled letters to Iovance, BMS, Novartis and Gilead’s Kite Pharma.

Learn more: www.emjreviews.com/emj-gold/new...

Lilly and Insilico strike historic $2.75bn AI alliance The Eli Lilly collaboration marks one of the largest generative AI-driven partnerships in the pharmaceutical industry to date.

Lilly and Insilico strike $2.75bn AI R&D alliance

EliLilly and Company has entered a major strategic collaboration with Insilico Medicine, marking a high-stakes expansion of generative AI in its pipeline

Learn more: www.emjreviews.com/emj-gold/new...

Gesynta’s endometriosis candidate enters phase 2 The study moves the non-hormonal endometriosis candidate into mid-stage testing in a field ripe for new therapeutic options.

Endometriosis treatment has long meant hormones, side effects and trade-offs.

What if the next wave targets inflammation instead?

A new phase 2 trial from Gesynta Pharma is underway, investigating a non-hormonal treatment for the condition.

Read now: www.emjreviews.com/emj-gold/new...

Takeda unveils restructure to fuel late-stage pipeline The company has announced a multi-year initiative aimed at delivering billions of annualised gross savings by 2028.

Takeda is betting big on a leaner, tech-driven future.

With a board-approved strategy aimed at delivering $1.25bn in savings by 2028, the Japanese pharma giant is preparing for a significant company restructure.

Explore more: www.emjreviews.com/emj-gold/new...

The Middle East conflict: pharma’s supply chain stress test The conflict is disrupting critical air freight routes, exposing vulnerabilities for biologics and low-margin generics.

What does the Middle East conflict mean for pharma supply chains?

The evolving situation in the Gulf isn’t just a supply chain disruption, it may threaten the integrity of ultra-cold chain biologics and the affordability of generics.

Read now: www.emjreviews.com/emj-gold/art...

UCB selects Georgia for new $2bn manufacturing hub The company has selected a site for its new plant to meet what it describes as a “growing demand” for its biologics pipeline.

Could Georgia be the next major hub for US life sciences?

UCB is expanding its US manufacturing operations with a new $2bn biologics hub in Georgia and will support the production of primarily neurology and immunology therapies.

Learn more: www.emjreviews.com/emj-gold/new...

AbbVie to sponsor leading US baseball league This collaboration marks the first of its kind for AbbVie and signals a massive national expansion of its ‘Striking Out Cancer’ initiative.

Can AbbVie help strike out cancer on a global scale? ⚾️

AbbVie is stepping up to the plate as Major League Baseball’s (MLB) first-ever official pharmaceutical partner, starting in the 2026 season.

Learn more: www.emjreviews.com/emj-gold/new...

#MLB #Strikeoutcancer #AbbVie

ABPI calls for NHS data use to boost trial recruitment The NHS is sitting on a gold mine of patient data that could, in the ABPI’s view, help rescue the UK’s faltering clinical trials sector.

The #ABPI is urging the UK to unlock #NHS data to fix a broken trial recruitment pipeline.

It says smarter use of anonymised records could speed up commercial studies, cut waste and keep the UK in the global race for pharma investment.

Learn more: www.emjreviews.com/emj-gold/new...

FDA backs shift to alternatives to animal testing The FDA has released draft guidance aimed at helping drug developers shift away from traditional animal testing as the standard.

The end of the animal testing default?

The FDA has released a roadmap for validating New Approach Methodologies (NAMs) to build safer, more effective therapies with higher regulatory confidence.

Read more on the shift to NAMs: www.emjreviews.com/emj-gold/new...

Roche expands AI factories for drug discovery Roche is supercharging drug discovery with a major AI expansion to transform how new medicines are developed.

Roche is scaling up its 'AI factories' with the help of NVIDIA GPUs.

By using thousands of specially trained models, Roche aims to reduce the time taken to detect and design high-potential clinical candidates from years to just months.

Read more: www.emjreviews.com/emj-gold/new...

Fridge-free vaccine shows promise in early trial A new fridge-free vaccine for tetanus and diphtheria has shown early promise in human trials – a potential win for global distribution.

Can vaccines withstand lower storage temperatures?

A new trial put the cold chain to the test with a tetanus and diphtheria vaccine, and the results were promising.

Learn more: www.emjreviews.com/emj-gold/new...

Survey: Half of US adults struggle to afford healthcare The share of Americans who feel financially secure about paying for basic healthcare has fallen to its lowest level since 2021.

Is basic healthcare becoming unaffordable for the average American?

The latest West Health–Gallup Healthcare Affordability Index revealed a troubling trend: perceptions of affordability are at their lowest since the survey began.

Find out more: www.emjreviews.com/emj-gold/new...

BioNTech co-founders leave to launch mRNA spin-off Co-founders, Prof Ugur Sahin and Prof Özlem Türeci, will depart to establish a new, independent biotechnology company.

#BioNTech enters a new phase of clinical evolution as co-founders Prof Ugur Sahin and Prof Özlem Türeci announce their planned exit to launch an independent mRNA venture.

Read the full story: www.emjreviews.com/emj-gold/new...

Think you're a medical affairs whizz?

Test your knowledge with our brand new quiz! From the origins of the medical affairs to the modern challenges of omnichannel engagement, see how well you know pharma’s ever-evolving function.

Take the quiz to see how you do: www.emjreviews.com/en-us/amj/em...

UK opens door to pharma manufacturing in space The UK Space Agency, MHRA and the CAA have announced a new regulatory roadmap for in-orbit manufacturing of pharmaceuticals.

The UK is taking the pharmaceutical supply chain into orbit. 🚀

A new regulatory roadmap from the UK Space Agency, MHRA and CAA clears the flight path for in-orbit drug manufacturing.

The UK is officially open for extraterrestrial R&D.

Read more: www.emjreviews.com/emj-gold/new...

Servier inks glycoengineering deal with kyron.bio The collaboration will leverage kyron.bio’s glycoengineering platform to optimise a specific antibody candidate selected by Servier.

Can a Parisian biotech startup revolutionise Servier’s antibody pipeline?

Servier has announced a strategic collaboration with kyron.bio to develop next-generation treatments for oncology and autoimmune diseases.

Learn more: www.emjreviews.com/emj-gold/new...

Is South Korea the new destination for drug development?

Roche thinks so. The healthcare giant has pledged $481m to help the nation become a strategic hub for global clinical trials and health innovation.

Learn more: www.emjreviews.com/emj-gold/new...

AI could unlock new cystic fibrosis protein target The hunt for new cystic fibrosis therapies is going digital, as the Cystic Fibrosis Foundation taps Antiverse for AI antibody design.

Cracking the CFTR protein code: Can AI finally target the 'undruggable'?

The Cystic Fibrosis Foundation has partnered with Antiverse to leverage its generative AI platform and deliver therapeutic-grade antibodies to CFTR and slashing R&D timelines.

Read more: www.emjreviews.com/emj-gold/new...